79 related articles for article (PubMed ID: 19714520)
21. Erdosteine: antitussive and anti-inflammatory effects.
Dal Negro RW
Lung; 2008; 186 Suppl 1():S70-3. PubMed ID: 18185958
[TBL] [Abstract][Full Text] [Related]
22. [Effects of elastase administration on experimental bleomycin-induced pulmonary fibrosis].
Narimatsu H; Nakajima H; Hiraizumi T; Aita S; Ide H; Takahashi T
Nihon Kyobu Shikkan Gakkai Zasshi; 1985 May; 23(5):557-62. PubMed ID: 2414502
[No Abstract] [Full Text] [Related]
23. ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis.
Martins V; Valença SS; Farias-Filho FA; Molinaro R; Simões RL; Ferreira TP; e Silva PM; Hogaboam CM; Kunkel SL; Fierro IM; Canetti C; Benjamim CF
J Immunol; 2009 May; 182(9):5374-81. PubMed ID: 19380784
[TBL] [Abstract][Full Text] [Related]
24. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis.
Ricevuti G; Mazzone A; Uccelli E; Gazzani G; Fregnan GB
Thorax; 1988 Aug; 43(8):585-90. PubMed ID: 3051508
[TBL] [Abstract][Full Text] [Related]
25. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis.
Olivieri D; Del Donno M; Casalini A; D'Ippolito R; Fregnan GB
Respiration; 1991; 58(2):91-4. PubMed ID: 1862257
[TBL] [Abstract][Full Text] [Related]
26. Short courses of low dose dexamethasone delay bleomycin-induced lung fibrosis in rats.
Chen F; Gong L; Zhang L; Wang H; Qi X; Wu X; Xiao Y; Cai Y; Liu L; Li X; Ren J
Eur J Pharmacol; 2006 May; 536(3):287-95. PubMed ID: 16581064
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner.
Ozyurt H; Yildirim Z; Kotuk M; Yilmaz HR; Yağmurca M; Iraz M; Söğüt S; Gergerlioglu S
J Appl Toxicol; 2004; 24(4):269-75. PubMed ID: 15300714
[TBL] [Abstract][Full Text] [Related]
28. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children.
Balli F; Bergamini B; Calistru P; Ciofu EP; Domenici R; Doros G; Dragomir D; Gherghina I; Iordachescu F; Murgoci G; Orasanu D; Plesca D; Vaccaro A; Assereto R
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):16-22. PubMed ID: 17256446
[TBL] [Abstract][Full Text] [Related]
29. A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Titti G; Lizzio A; Termini C; Negri P; Fazzio S; Mancini C
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):402-7. PubMed ID: 10984014
[TBL] [Abstract][Full Text] [Related]
30. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.
Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
Pulm Pharmacol Ther; 2018 Feb; 48():185-194. PubMed ID: 29233650
[TBL] [Abstract][Full Text] [Related]
31. In vivo evidence suggesting a role for purine-catabolizing enzymes in the pathogenesis of cisplatin-induced nephrotoxicity in rats and effect of erdosteine against this toxicity.
Söğüt S; Kotuk M; Yilmaz HR; Ulu R; Ozyurt H; Yildirim Z
Cell Biochem Funct; 2004; 22(3):157-62. PubMed ID: 15124180
[TBL] [Abstract][Full Text] [Related]
32. [Effects of metalloproteinases on pulmonary fibrosis by bleomycin in rats].
Liu X; Xu S; He B; Tan W
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Feb; 22(2):98-100. PubMed ID: 11820951
[TBL] [Abstract][Full Text] [Related]
33. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease.
Marchioni CF; Moretti M; Muratori M; Casadei MC; Guerzoni P; Scuri R; Fregnan GB
Lung; 1990; 168(5):285-93. PubMed ID: 2126836
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of bleomycin-induced pulmonary fibrosis by lipopolysaccharide.
Phan SH; Fantone JC
Lab Invest; 1984 May; 50(5):587-91. PubMed ID: 6201676
[TBL] [Abstract][Full Text] [Related]
35. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats.
Okada T; Sugie I; Aisaka K
Lymphokine Cytokine Res; 1993 Apr; 12(2):87-91. PubMed ID: 7686780
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.
Brewer GJ; Dick R; Ullenbruch MR; Jin H; Phan SH
J Inorg Biochem; 2004 Dec; 98(12):2160-7. PubMed ID: 15541506
[TBL] [Abstract][Full Text] [Related]
37. Prevention of pulmonary complications of pneumoperitoneum in rats.
Karapolat S; Gezer S; Yildirim U; Dumlu T; Karapolat B; Ozaydin I; Yasar M; Iskender A; Kandis H; Saritas A
J Cardiothorac Surg; 2011 Feb; 6():14. PubMed ID: 21303502
[TBL] [Abstract][Full Text] [Related]
38. [Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion].
Aubier M; Berdah L
Rev Mal Respir; 1999 Sep; 16(4):521-8. PubMed ID: 10549062
[TBL] [Abstract][Full Text] [Related]
39. Bleomycin-induced pulmonary fibrosis in the rat. Prevention with an inhibitor of collagen synthesis.
Kelley J; Newman RA; Evans JN
J Lab Clin Med; 1980 Dec; 96(6):954-64. PubMed ID: 6159435
[TBL] [Abstract][Full Text] [Related]
40. Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis.
Sriram N; Kalayarasan S; Sudhandiran G
Chem Biol Interact; 2009 Jul; 180(2):271-80. PubMed ID: 19497426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
